Abstract：【Objective】To investigate the effect of sodium glucose cotransporter 2(SGLT-2) inhibitor on vascular endothelial cells in diabetes mice. 【Methods】Twenty four SPF 8-week old male ICR mice were intraperitoneally injected with low-dose streptozotocin(STZ)(50 mg/kg) to establish a diabetes model. The model was successfully established. They were randomly divided into a model group and a treatment group(Daggligin intervention treatment for 12 weeks). Six mice were used as the control group, and physiological saline was injected subcutaneously. Three groups were all fed with regular feed, and the changes in body weight and blood glucose of mice were dynamically observed every week. The plasma levels of tumor necrosis factor alpha(TNF-α), interleukin-1β(IL-1β), monocyte chemotactic factor-1(MCP-1), superoxide dismutase(SOD), and malondialdehyde(MDA) were compared among the three groups of mice. 【Results】 From the 2nd weekend to the 12th weekend, both the model group and the treatment group had lower body weight than the control group, while the treatment group had higher body weight than the model group, with a statistically significant difference(P<0.05). Compared with the control group, the blood glucose levels in the model group and treatment group were significantly increased, and the difference was statistically significant(P<0.05); Compared with the model group, the blood glucose levels of the treatment group mice significantly decreased from the 3rd to the 12th weekend, and the difference was statistically significant(P<0.05). The plasma levels of TNF-α, IL-1β, and MCP-1 in the model group were significantly higher than those in the control group, while the plasma levels of TNF-α, IL-β, and MCP-1 in the treatment group were significantly lower than those in the model group, with statistical significance(P<0.05). The plasma SOD level in the model group was lower than that in the control group, while the plasma SOD level in the treatment group was higher than that in the model group, with a statistically significant difference(P<0.05); Compared with the control group, the plasma MAD level in the model group was higher than that in the control group, while the plasma MAD level in the treatment group was lower than that in the model group, with a statistically significant difference(P<0.05). 【Conclusion】 SGLT-2 inhibitor can effectively inhibit the release of inflammatory factors from vascular endothelial cells in diabetes mice, and improve the function of vascular endothelial cells.
[1] 包丽雯,刘荣宸,严芳英,等.钠-葡萄糖共转运体2抑制剂治疗心血管疾病的研究进展[J].中华心血管病杂志,2020,48(4):339-343. [2] 葛均波,霍勇,高秀芳,等.改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J].中国循环杂志,2020,35(3):231-238. [3] KANG J,KIM H L,SEO J B,et al.Endothelial function estimated by digital reactive hyperemia in patients with atherosclerotic risk factors or coronary artery disease[J].Heart Vessels,2018,33(7):706-712. [4] LAHNWORG S, PALEE S, APAIJAI N, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury[J].Cardiovasc Diabetol,2020,19(1):91. [5] JAMWAL S,SHARMA S.Vascular endothelium dysfunction: a conservative target in metabolic disorders[J].Inflamm Res,2018,67(5):391-405. [6] ZHOU Y, WU W.The sodium-glucose co-transporter 2 inhibitor, empaglifozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway[J].Cell Physiol Biochem,2017,41(6):2503-2512. [7] LI C G, ZHANG J,XUE M, et al. SGLT2 inhibition with empaglifozin attenuates myocardial oxidative stress and fbrosis in diabetic mice heart[J].Cardiovasc Diabetol,2019,18(1):15. [8] PACKER M. Autophagy-dependent and independent modulation of oxidative and organellar stress in the diabetic heart by glucose lowering drugs[J].Cardiovasc Diabetol,2020,19(1):62. [9] DAWWAS G K, SMITH S M, PARK H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J].Diabetes Obes Metab,2019,21(1):28-36. [10] ZHANG N N, FENG B, MA X X, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction [J].Cardiovasc Diabetol,2019,18(1):107-122. [11] 赵为陈,沈炳香,何春远,等. 盘状结构域受体 1 对高糖诱导血管内皮凋亡的影响[J].中国药理学通报,2020,36(6):821-826. [12] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type2 diabetes[J].N Engl J Med,2019,308(4):347-357. [13] 李吉萍,袁野,张文友. 西洋参茎叶皂苷对糖尿病大鼠氧化损伤和血管内皮功能的影响[J].中国药理学通报,2017,33(12):1698-1702. [14] LEE H J, MARIAPPAN M M, NORTON L,et al. Proximail tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury[J].JCI Insight,2021,6(3): e14319. [15] VAN BOMMEL E J M, MUSKIET M H A, VAN BAAR M J B,et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pro-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial[J].Kidney Int,2020, 97(1): 202-212.
2024, Vol. 41 
